RecruitingNCT06517719
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Real-world Experience With Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, Multicenter, Prospective Cohort Study
Sponsor
Novartis Pharmaceuticals
Enrollment
500 participants
Start Date
Sep 4, 2024
Study Type
OBSERVATIONAL
Summary
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 99 Years
Inclusion Criteria4
- Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.
- ≥ 18 years old at the time of enrollment
- Written informed consent must be obtained prior to any data collection
- Willing to participate in Quality of Life post treatment date collection for 1 year
Exclusion Criteria2
- Patients must not meet the following exclusion criterion during the identification period:
- \- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan
Interventions
OTHERlutetium (177Lu) vipivotide tetraxetan
This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.
Locations(35)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06517719